APA (7th ed.) Citation

Lei, W., Zhao, A., Liu, H., Yang, C., Wei, C., Guo, S., . . . Qian, W. (2024). Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell Discovery, 10(1), 1. https://doi.org/10.1038/s41421-023-00625-0

Chicago Style (17th ed.) Citation

Lei, Wen, et al. "Safety and Feasibility of Anti-CD19 CAR T Cells Expressing Inducible IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-cell Lymphoma." Cell Discovery 10, no. 1 (2024): 1. https://doi.org/10.1038/s41421-023-00625-0.

MLA (9th ed.) Citation

Lei, Wen, et al. "Safety and Feasibility of Anti-CD19 CAR T Cells Expressing Inducible IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-cell Lymphoma." Cell Discovery, vol. 10, no. 1, 2024, p. 1, https://doi.org/10.1038/s41421-023-00625-0.